// App-Quantinova.ai

CT217 : Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors

Researchers

Presenter

  • Zhongwu Lai

Principal Investigators

  • Talia Golan

  • Hedy L. Kindler

  • Brian Dougherty

  • Athena Matakidou

  • Liqin Dong

  • Gershon Locker

  • Elizabeth A. Harrington

Medical Centers

  • AstraZeneca, Waltham, MA

  • The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel

  • The University of Chicago Medical Center, Chicago, IL

  • Centre for Genomics Research Discovery Sciences BioPharmaceuticals R&D AstraZeneca Cambridge UK Cambridge United Kingdom

  • Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA

  • Translational Medicine, Early Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom

Locations

  • United States

  • Israel

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Cyclin Dependent Kinase Inhibitor 2A

  • KRAS proto-oncogene, GTPase

  • Tumor protein p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Methadone hydrochloride

  • Olaparib

  • TP53

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02184195

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved